Overview

A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)

Status:
Completed

Trial end date:
2020-02-17

Target enrollment:

Participant gender:

Summary

Patients 18 years of age and older with clinical stages IIA, IIB, IIIA, IIIB, IVA cervical carcinoma limited to the pelvis will receive twice daily oral nelfinavir (NFV) and weekly IV cisplatin in combination as radiosensitizers with daily whole pelvic external beam and intracavitary radiation brachytherapy.

Phase:

Phase 1

Details

Lead Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Treatments:

Cisplatin
Nelfinavir